News

Treatment Response in HCV infection can be monitored with serologic detection of HCV antigen rather than molecular detection of HCV-RNA.

Overall, the data showed that patients in the treat-and-extend group also received fewer injections in comparison to the monthly group.

Maternal HCV infections at the time of a baby’s delivery almost doubled to 3.4 per 1000 live births in 2014, from 1.8 per 1000 in 2009.

The U.S. Food and Drug Administration has approved a third indication for olaparib tablets (Lynparza).

The Antimicrobial Drugs Advisory Committee voted 12-3 against supporting whether Aradigm Corporation provided substantial evidence for the safety and efficacy of inhaled ciprofloxacin dispersion.

Results from a study report that behavioral interventions, like environmental enrichment, can reduce the functional deficit experienced by patients with Rett syndrome.

The influenza vaccine can now be used to protect recommended persons aged 6 months and older.

In this Rare Connections program, Martha Raymond; Founder of the Raymond Foundation, Executive Director of Michael’s Mission, and the Co-Chair of the GI Cancers Alliance meets with Sarah Bennett, a cholangiocarcinoma survivor to highlight the space.

Having a second sexually-transmitted infection can significantly increase the chance that an HIV-positive pregnant woman passes the virus on to her infant.

Mesenchymal stem cell transplantation showed long-lasting and consistent effects on opioid tolerance and opioid-induced hyperalgesia in rat and mouse models.

Color Doppler imaging showed that patients with AMD had general vascular disorder in all arteries evaluated.

A new meta-analysis suggests ART therapy has a positive impact on HPV and cervical cancer rates.

The indication will limit the availability of prescription opioid cough and cold medicines for patients younger than 18 years old.

Retrophin has committed $3 million over the next 6 years to support the work of the Children’s National Rare Disease Institute, the first Center of Excellence for the National Organization for Rare Disorders.

Lipocene's TLANDO was recommended against by a vote of 13-6.

Roaming monkeys in Florida are being removed by the state’s wildlife managers because of the growing fear that they are excreting a virus that can be dangerous to humans.

At the 36th Annual J.P. Morgan Healthcare Conference, uniQure announced that in 2018, the company intends to advance its gene therapy AMT-061 into a pivotal study for hemophilia B.

Jak inhibitors could represent an add-on therapy to existing antiretrovirals, addressing an unmet clinical need for HIV-infected individuals.

From January 2012 to July 2017, the FDA reportedly received 79 Medical Device Reports (MDRs) pertaining to pneumothorax events, including 16 deaths.

Higher rates of stillbirths, the need for emergency Caesarean sections, and infant mortality have all been associated with both type 1 and type 2 diabetes

Migraine patients have been found to suffer more than nearly all other chronic pain patients but can be relieved by surgery.

Ribavirin is still required in the era of direct-acting antivirals and can be optimally dosed for difficult-to-cure hepatitis C.

A new study looked at thousands of asthma patients in order to better understand the genetic associations of asthma.

After discovering the fate of a former teammate’s child, wrestlers at Wells High School in Maine are using their sport as an incentive to raise money for Sanfilippo Syndrome.

On Monday, Shire announced that it plans to reorganize its business structure and create two distinct operational divisions; one in rare disease and another in neuroscience.

The study is the first of 3 in the International Diabetes Closed Loop trial, funded by the National Institute of Health.

Data published in the Orphanet Journal of Rare Diseases suggests that endurance training could have a positive impact in Huntington’s disease patients, much like it has in anyone else.

Earlier this week, NuMedii, Inc. announced the official formation of an Idiopathic Pulmonary Fibrosis (IPF) Advisory Board.

Avadel Pharmaceuticals announced this morning that FT 218, its once-nightly product for the treatment of narcolepsy, has been granted Orphan Drug Designation by the U.S. Food and Drug Administration.

The newly approved system is an alternative to systemic opioids for patients.